Amplia Therapeutics Limited
INNMF · OTC
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.30 | 0.08 | -0.01 |
| FCF Yield | -11.89% | -20.20% | -3.55% | -10.63% |
| EV / EBITDA | -5.28 | -4.38 | -10.20 | -3.81 |
| Quality | ||||
| ROIC | -9.92% | -17.84% | -21.48% | -16.16% |
| Gross Margin | 0.00% | 94.13% | 94.95% | 83.51% |
| Cash Conversion Ratio | 1.83 | 1.52 | 0.42 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.43% | 73.84% | 80.77% | 305.37% |
| Free Cash Flow Growth | 11.25% | -387.36% | 26.09% | 55.22% |
| Safety | ||||
| Net Debt / EBITDA | 4.25 | 2.72 | 1.61 | 0.52 |
| Interest Coverage | -1,522.12 | 0.00 | 0.00 | -104.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,768.21 | -865.98 | -1,664.38 | -293.85 |